We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Biogen Snags Accelerated Approval for ALS Drug Based on Biomarker Data
Biogen Snags Accelerated Approval for ALS Drug Based on Biomarker Data
Biogen has received an Accelerated Approval for Qalsody (tofersen) for the treatment of an extremely rare genetic form of amyotrophic lateral sclerosis (ALS) despite less than stellar trial results.